Professor Emeritus

Email: [email protected]

Qualifications

1983 Ph.D., University of Miami School of Medicine Miami, Florida

1977 B.S., University of South Florida Tampa, Florida

Publications (Selected)

1. Goodwin H, Zhang Q, Mujumdar V, et al. PTEN loss of function encodes sensitivity to multitargeted small molecule CDK4/6-CDK9-AURKA/B inhibitor, LCI133, and other CDK9 inhibitors[J]. Cancer Research, 2026, 86(7_Supplement): 1900-1900.

2. Foureau A I, Wajih N, McHale C C, et al. Multitargeted kinase inhibitor LCI139 overcomes chemotherapy resistance in patient-derived non small cell lung cancer organoids by harnessing intrinsic and extrinsic apoptosis[J]. Cancer Research, 2026, 86(7_Supplement): 3171-3171.
3. Maddeboina K, Pal D, Yada B, et al. Discovery of a “First-in-Class” Selective Multikinase (CDK4/6/9-AURKA/B) Inhibitor Mujumdar V, Maddeboina K, Pal D, et al. LCI139: In silico design of a novel multitarget small molecular inhibitor for the treatment of PTEN-mutant endometrial adenocarcinoma[J]. Gynecologic Oncology, 2024, 190: S184-S185., LCI133, for Neuroblastoma[J]. Journal of Medicinal Chemistry, 2025, 68(22): 24024-24046.
4. Zhang Q, Mujumdar V, Delara R, et al. Preclinical development of novel small molecule multitarget inhibitor LCI133 for endometrial adenocarcinoma[J]. Gynecologic Oncology, 2025, 200: 216-217.
5. Ivanina Foureau A V, McHale C C, Dryden H L, et al. A novel class of multitarget small molecule PI3K-CDK4/6-CDK9-AURAKA/B inhibitor harnesses Warburg effect against non-small cell lung cancer[J]. Cancer Research, 2025, 85(8_Supplement_1): 369-369.
6. Mani R, Benrashid S, Templeton M D, et al. TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas[J]. Iscience, 2025, 28(6).
7. Mujumdar V, Maddeboina K, Pal D, et al. LCI139: In silico design of a novel multitarget small molecular inhibitor for the treatment of PTEN-mutant endometrial adenocarcinoma[J]. Gynecologic Oncology, 2024, 190: S184-S185.
8. Mujumdar V, Delara R, Dryden H L, et al. In silico design of novel multitarget small molecule inhibitors to treat PTEN-mutant endometrial carcinoma[J]. 2024.
9. Pandey K, Acharya A, Pal D, et al. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2[J]. Antiviral research, 2024, 227: 105904.
10. Pal D, Arditti P M, Maddeboina K, et al. The Novel CDK9/CDK4/6/PI3K Triple Inhibitor LCI139 for the Treatment of MYC-Driven Mantle Cell Lymphoma[J]. Blood, 2023, 142: 4180.
11. McHale C C, Delara R, Pal D, et al. 1425 The novel small molecule multitarget inhibitor LCI133 sensitizes endometrial carcinoma to TRAIL-mediated apoptosis[J]. 2023.
12. Vann K R, Acharya A, Jang S M, et al. Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection[J]. Structure, 2022, 30(9): 1224-1232. e5.
13. Acharya A, Pathania A S, Pandey K, et al. PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron[J]. Clinical and Translational Medicine, 2022, 12(4): e806.
14. Ruan Y, Kim H N, Ogana H A, et al. Preclinical evaluation of a novel dual targeting PI3kδ/BRD4 inhibitor, SF2535, in B-cell acute lymphoblastic leukemia[J]. Frontiers in oncology, 2021, 11: 766888.
15. Pathania A S, Prathipati P, Abdul B A A, et al. COVID-19 and cancer comorbidity: therapeutic opportunities and challenges[J]. Theranostics, 2021, 11(2): 731.

Personal Details

http://researchgate.net/profile/Donald-Durden

WoS Researcher ID: PDT-0495-2025